DE69329802D1 - Syndecan-stimulierung der zellulären differenzierung - Google Patents

Syndecan-stimulierung der zellulären differenzierung

Info

Publication number
DE69329802D1
DE69329802D1 DE69329802T DE69329802T DE69329802D1 DE 69329802 D1 DE69329802 D1 DE 69329802D1 DE 69329802 T DE69329802 T DE 69329802T DE 69329802 T DE69329802 T DE 69329802T DE 69329802 D1 DE69329802 D1 DE 69329802D1
Authority
DE
Germany
Prior art keywords
syndecan
methods
cellular differentiation
stimulation
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69329802T
Other languages
English (en)
Other versions
DE69329802T2 (de
Inventor
Anni Maija Waerri
Leena Maria Alanen-Kurki
Petri Olli Viljami Auvinen
Panu Mikko Jaakola
Markku Tapani Jalkanen
Sirpa Marianne Leppae
Markku Sakari Mali
Tapani Antero Vihinen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotie Therapies Corp
Original Assignee
Biotie Therapies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25534102&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69329802(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biotie Therapies Corp filed Critical Biotie Therapies Corp
Publication of DE69329802D1 publication Critical patent/DE69329802D1/de
Application granted granted Critical
Publication of DE69329802T2 publication Critical patent/DE69329802T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69329802T 1992-12-01 1993-12-01 Syndecan-stimulierung der zellulären differenzierung Expired - Fee Related DE69329802T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98842792A 1992-12-01 1992-12-01
PCT/FI1993/000514 WO1994012162A1 (en) 1992-12-01 1993-12-01 Syndecan stimulation of cellular differentiation

Publications (2)

Publication Number Publication Date
DE69329802D1 true DE69329802D1 (de) 2001-02-01
DE69329802T2 DE69329802T2 (de) 2001-07-19

Family

ID=25534102

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69329802T Expired - Fee Related DE69329802T2 (de) 1992-12-01 1993-12-01 Syndecan-stimulierung der zellulären differenzierung

Country Status (9)

Country Link
EP (1) EP0671909B1 (de)
JP (1) JPH08503848A (de)
AT (1) ATE198271T1 (de)
AU (1) AU687767B2 (de)
CA (1) CA2150714C (de)
DE (1) DE69329802T2 (de)
DK (1) DK0671909T3 (de)
ES (1) ES2154290T3 (de)
WO (1) WO1994012162A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726058A (en) * 1992-12-01 1998-03-10 Jalkanen; Markku Syndecan stimulation of cellular differentiation
US6492344B1 (en) 1993-12-01 2002-12-10 Biotie Therapies Corp. Syndecan enhancer element and syndecan stimulation of cellular differentiation
US6017727A (en) * 1994-03-07 2000-01-25 Biotie Therapies Ltd. Syndecan enhancer element and syndecan stimulation of cellular differentiation
US5851993A (en) * 1994-06-13 1998-12-22 Biotie Therapies Ltd. Suppression of tumor cell growth by syndecan-1 ectodomain
US6413533B1 (en) 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
AU2003203589B2 (en) * 1998-05-07 2005-10-27 The University Of Tennessee Research Corporation A method for chemoprevention of prostate cancer
WO1999056739A1 (en) * 1998-05-07 1999-11-11 The University Of Tennessee Research Corporation A method for chemoprevention of prostate cancer
US6632447B1 (en) 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6413534B1 (en) 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8806893D0 (en) * 1988-03-23 1988-04-27 Unilever Plc Cosmetic composition
JPH04224522A (ja) * 1990-04-27 1992-08-13 Merck & Co Inc 繊維芽細胞増殖因子含有組成物による禿頭症の治療又は予防方法
US5147854A (en) * 1990-05-22 1992-09-15 Hoffmann-La Roche Inc. Tgf-b compositions and method
DE69129417T2 (de) * 1991-01-15 1998-11-05 Biotie Therapies Oy Nachweis des syndecangehalts in biologischen materialien, wie geweben und körperflüssigkeiten, zur anzeige der bösartigen umwandlung von zellen

Also Published As

Publication number Publication date
JPH08503848A (ja) 1996-04-30
ES2154290T3 (es) 2001-04-01
AU5564994A (en) 1994-06-22
EP0671909A1 (de) 1995-09-20
DE69329802T2 (de) 2001-07-19
WO1994012162A1 (en) 1994-06-09
DK0671909T3 (da) 2001-03-19
CA2150714C (en) 2002-02-05
ATE198271T1 (de) 2001-01-15
CA2150714A1 (en) 1994-06-09
EP0671909B1 (de) 2000-12-27
AU687767B2 (en) 1998-03-05

Similar Documents

Publication Publication Date Title
ES2074867T3 (es) Derivados de quinazolina para potenciar la actividad antitumoral.
DE3883374T2 (de) Acylatiertes uridin und cytidin und deren verwendungen.
DE69738615D1 (de) Verwendung von glp-1 oder analogen zur behandlung von myokardischem infarkt
DE69533581D1 (de) Sprühbare zubereitungen enthaltend dispernierten pulvers sowie dessen anwendungsverfahren
NZ505011A (en) Expression vectors and cell lines expressing VEGF-D and method of treating melanomas
EP0151989A3 (en) Means for the treatment of cardiac diseases
ES2082198T3 (es) Inhibidores de esteroide-sulfatasa.
DK0902789T3 (da) Androstenderivater
ATE227717T1 (de) 3-pyridylenantiomere und ihre verwendung als analgetika
DE69426334T2 (de) Parenterales Busulfan zur Behandlung von malignen Krankheiten
NZ301645A (en) (R)-(-)-methyl phenyl oxazolidinone derivatives, pharmaceutical preparations and use for treating TNF stimulated diseases
ATE34077T1 (de) Hautbehandlungsmittel.
ATE198271T1 (de) Syndecan-stimulierung der zellulären differenzierung
DE69535081D1 (de) Verwendung von Prostaglandin A oder dessen Derivaten zur Behandlung von Psoriasis
ATE217514T1 (de) Verwendung von bradykininantagonisten zur induzierung oder stimulation des haarwachstums und/oder zur verlangsamung des haarausfalls
NO994330L (no) Metode for behandling av en tumor
DK0637306T3 (da) 4-Imidomethyl-1-[2'-phenyl-2'-oxoethyl]-piperidiner som serotonin-5HT2-antagonister, deres fremstilling og anvendelse til terapi
DE68918562T2 (de) Menschliche myeloperoxidase und therapeutische verwendung.
EE03170B1 (et) Perifeerse vere mononukleaarsete rakkude tsütotoksilise aktiivsuse stimuleerimine IL-10 abil
EP0410921A3 (en) Dressing for transcutaneous application of active substances for therapeutic or cosmetic purposes
DE69724793D1 (de) Ethen enthaltende lösungen sowie deren verwendung in heil- und vorbeugeverfahren
NO870001D0 (no) Farmasoeytisk baerer for nedsettelse av stroemning av terapaeutisk og kosmetisk farmakologisk aktive midler gjennom huden.
DE68906028T2 (de) Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: BIOTIE THERAPIES CORP., TURKU, FI

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee